News

Neurotech Reports, the publisher of Neurotech Business Report, announced the winners of the 2020 Gold Electrode Awards during the 20th Annual Neurotech Leaders Forum, which took place November 16-17 in San Francisco and also via Zoom. The award for best new product went to Axonics Modulation for its R-SNM sacral nerve stimulation system. The award for most promising startup went to Synchron Inc., which is developing a novel brain-computer interface that is migrated to the brain via the cerebral vasculature.

Neurotech investigators and entrepreneurs who received funding from two key programs supported Projects Agency met with interested venture capital and strategic firm investors during the inaugural Translational Neurotech Showcase earlier this month. The invitation-only event, which was conducted via remote video conference because of the Coronavirus pandemic, took place immediately after the 20th Annual Neurotech Leaders Forum.

Neurotech Reports, the publisher of Neurotech Business Report, announced that several new and emerging neurotechnology startup firms will present at the 20th Annual Neurotech Leaders Forum on November 16-17, 2020. The hybrid event takes place at the Embassy Suites SFO and on-line via Zoom. Among the promising new neurotech firms added to the agenda are NeuroGeneces, which has developed a noninvasiv…

When we launched this publication in 2001, we predicted that the neurotechnology industry would expand significantly in the years to follow. We were certainly right about that. One of the things we were wrong about is the speed with which consumer applications of neurotechnology would emerge. We expected that computer hardware and software vendors would be chomping at the bit to integrate neural data into their products, and that frankly didn’t happen.

The neurotechnology market for treating migraine continues to show promise, despite some uncertainties caused early entrants in the space. While the commercial failures have caused concern in some patient advocacy groups, the wealth of product alternatives will likely keep this product segment on an upward trajectory. In August, eNeura Inc., a manufacturer of a handheld TMS device for treating migraine, filed for Chapter 7 bankruptcy and no other vendor has yet emerged to continue marketing their device.

The neurotechnology market for treating migraine continues to show promise, despite some uncertainties caused early entrants in the space. While the commercial failures have caused concern in some patient advocacy groups, the wealth of product alternatives will likely keep this product segment on an upward trajectory. In August, eNeura Inc., a manufacturer of a handheld TMS device for treating migraine, filed for Chapter 7 bankruptcy and no other vendor has yet emerged to continue marketing their device.

Kernel, the Venice, CA developer of brain sensing and analysis systems launched in 2016 , took to the Internet earlier this month to demonstrate the company’s new Flow headset. The livestream featured interviews with key neuroscientists who discussed the function and applications of the new device. Kernel Flow is a noninvasive brain interface which records real-time, cortical hemodynamics to establish precise patterns of brain activity.

When new neurotech therapies go right, everyone is happy. Patients get access to a therapy that addresses their disorder. Vendors get revenues from device sales, upgrades, and service. Clinicians get a new base of patients and gain expertise in their field. And payers get assurance that their subscribers are being cared for in a cost-effective manner. When new neurotech therapies go wrong, it’s mostly the investors and entrepreneurs who are unhappy.

Tufts University, located on campuses in Boston, Medford/Somerville, and Grafton, MA, is recognized among the premier research universities in the U.S. The university recently raised its profile among neurotechnology researchers with the donation of technology and other assets from BrainGate Inc. and its former CEO Jeff Stibel, a Tufts alumnus. Stibel acquired much of the BrainGate IP, including the trademark for the term BrainGate, in 2009 from Cyberkinetics Inc., which closed its doors soon thereafter.

While the Mid-scale Research Infrastructure Workshop may have a long name, its impact was nothing short of impressive. Unlike most of the conferences and workshops these days, this one was designed to be 100 percent online since it was first imagined. Led University of California, San Diego, the National Science Foundation-funded event was meant to examine current state of the art in neuromodulatio…